Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silk fibroin + chlorhexidine is a combination of silk fibroin, a natural protein polymer derived from silkworm cocoons, and chlorhexidine, a broad-spectrum antimicrobial agent. This combination is primarily used in the development of advanced wound dressings and drug delivery systems. Silk fibroin serves as a biocompatible scaffold or film that can be loaded with hydrophilic drugs like chlorhexidine to provide controlled release at the site of application[1][4]. The mechanism leverages the structural properties of silk fibroin for tissue regeneration and healing, while chlorhexidine provides local antimicrobial action to prevent infection[1][2][5]. The blend can be formulated as films or hydrogels for use in wound care, where it offers benefits such as enhanced mechanical strength, biocompatibility, biodegradability, and sustained drug release profiles[1][2][5]. Research indicates that loading with chlorhexidine does not significantly alter the physical properties of the silk fibroin film but enables effective antibacterial activity at wound sites[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silk fibroin + chlorhexidine.